Ontario Teachers Pension Plan Board Sells 43,709 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Ontario Teachers Pension Plan Board decreased its holdings in shares of Inari Medical, Inc. (NASDAQ:NARI) by 75.7% during the third quarter, HoldingsChannel reports. The fund owned 14,047 shares of the company’s stock after selling 43,709 shares during the quarter. Ontario Teachers Pension Plan Board’s holdings in Inari Medical were worth $579,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently modified their holdings of NARI. Bamco Inc. NY lifted its stake in Inari Medical by 27.4% during the first quarter. Bamco Inc. NY now owns 777,152 shares of the company’s stock worth $37,288,000 after purchasing an additional 167,000 shares during the last quarter. Lighthouse Investment Partners LLC purchased a new position in Inari Medical during the 2nd quarter valued at about $2,145,000. Aigen Investment Management LP bought a new position in shares of Inari Medical during the third quarter valued at approximately $428,000. Integral Health Asset Management LLC increased its position in Inari Medical by 100.0% during the 2nd quarter. Integral Health Asset Management LLC now owns 400,000 shares of the company’s stock valued at $19,260,000 after purchasing an additional 200,000 shares during the period. Finally, The Manufacturers Life Insurance Company raised its stake in Inari Medical by 1,219.9% in the second quarter. The Manufacturers Life Insurance Company now owns 394,901 shares of the company’s stock worth $19,014,000 after buying an additional 364,983 shares in the last quarter. 90.98% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

NARI has been the topic of several analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Inari Medical in a report on Tuesday, October 29th. Canaccord Genuity Group boosted their price objective on Inari Medical from $71.00 to $74.00 and gave the company a “buy” rating in a research report on Tuesday, October 29th. William Blair began coverage on Inari Medical in a research report on Thursday, July 25th. They set an “outperform” rating for the company. Stifel Nicolaus began coverage on shares of Inari Medical in a research note on Tuesday, September 17th. They issued a “hold” rating and a $50.00 price objective for the company. Finally, Wells Fargo & Company decreased their price target on Inari Medical from $84.00 to $65.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st. Six research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $58.89.

Insider Activity

In other Inari Medical news, CFO Mitch C. Hill sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $45.13, for a total transaction of $135,390.00. Following the completion of the transaction, the chief financial officer now owns 179,600 shares in the company, valued at $8,105,348. The trade was a 1.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director William Hoffman sold 40,000 shares of Inari Medical stock in a transaction on Monday, September 16th. The stock was sold at an average price of $45.83, for a total transaction of $1,833,200.00. Following the sale, the director now directly owns 643,296 shares of the company’s stock, valued at approximately $29,482,255.68. This trade represents a 5.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 186,000 shares of company stock valued at $8,990,990 in the last quarter. Insiders own 10.60% of the company’s stock.

Inari Medical Price Performance

NASDAQ:NARI opened at $49.80 on Friday. The firm has a market capitalization of $2.92 billion, a price-to-earnings ratio of -37.07 and a beta of 0.96. Inari Medical, Inc. has a 1-year low of $36.73 and a 1-year high of $67.13. The company’s 50-day moving average is $45.52 and its two-hundred day moving average is $47.19.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.